Skip to content

The Role of Stress Neuromodulators in Decision Making Under Risk (Part II)

The Role of Stress Neuromodulators in Decision Making Under Risk

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05318248
Acronym
SID2
Enrollment
82
Registered
2022-04-08
Start date
2022-03-01
Completion date
2023-03-31
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress

Brief summary

The aim of the proposed project is to combine precise pharmacological manipulation of the noradrenergic system with behavioral modeling of memory processes, and fMRI methods to study the effect of a pharmacologically induced blockade of the noradrenergic system on memory processes. Behaviorally, the investigators will focus on the effect of the noradrenergic blockade on working memory performance, and recognition memory.

Detailed description

Affective states like acute stress can influence cognition, i.e., memory processes. Physiologically, acute stress elicits an array of autonomic and endocrine responses, including a fast release of norepinephrine from the locus coeruleus noradrenergic (LC NA) system. Compelling evidence shows that in healthy humans, stimulation of the noradrenergic system increases memory performance whereas noradrenergic blockade reduces memory performance. Functional magnetic resonance imaging (fMRI) studies have shown that manipulations of the noradrenergic system affects responsiveness and connectivity within networks that are important for autonomic-neuroendocrine control and temporal and spatial attention orientation. So far, no study investigated the neural underpinnings of memory processes after a pharmacologically induced noradrenergic blockade. The aim of the proposed project is to combine precise pharmacological manipulation of the noradrenergic system with behavioral modeling of distinct memory processes, and fMRI methods to study the effect of a pharmacologically induced blockade of the noradrenergic system on two distinct memory processes. Behaviorally, the investigators will focus on the effect of the noradrenergic blockade on working memory performance, and recognition memory. Participants are randomly assigned to one of two groups: (A) clonidine, or (B) placebo.

Interventions

0,15mg Clonidin orally versus placebo pill

DRUGPlacebo

placebo pill

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* right handed, high-school diploma

Exclusion criteria

* former & present DSM-5 axis I disorders, medication,

Design outcomes

Primary

MeasureTime frameDescription
Working Memory (n-back task)11 minutesBehavioral outcome of emotional two-back task = number of correct answers / button presses
Recognition Memory (word list learning)25 minutesBehavioral outcome of word recognition task = number of correctly recognized words
Blood-oxygen-level-dependent (BOLD) response46 minutesfMRI data

Secondary

MeasureTime frameDescription
blood pressure2.5 hoursTreatment check
Heart rate2.5 hoursTreatment check
salivary cortisol2.5 hoursTreatment check

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026